BACKGROUND: @entity10127 is an enhanced-affinity @entity1536 with potent activity against lower respiratory tract pathogens. OBJECTIVE: The efficacy and safety of a 5-day course of @entity10127 were compared with those of a standard 7-day regimen of @entity4581 in @entity1 with an @entity3311 ( @entity3311 ). The impact of treatment on the long-term (26 weeks) clinical outcome was also assessed. METHODS: The acute phase of this randomized, double-blind study was performed in 93 centers in 7 countries. Adult @entity1 (age >40 years) with a history of chronic @entity3617 and an Anthonisen type 1 acute exacerbation (increased @entity1353 , cough, and sputum purulence) were eligible. @entity1 receiving systemic @entity230 at a dose of >10 mg @entity229 or the equivalent were excluded. @entity1 were randomized to receive @entity10127 320 mg once daily for 5 days or @entity4581 500 mg twice daily for 7 days. Clinical and bacteriologic response rates were assessed at the end-of-therapy visit (days 8-12), the week 2-3 follow-up visit (days 13-24), and the week 4-5 follow-up visit (days 25-38). The long-term phase (26 weeks), which included US and Canadian @entity1 only, evaluated the proportion of @entity1 who remained free of a recurrence of @entity3311 requiring additional antimicrobial therapy after resolution of the initial episode. RESULTS: Seven hundred twelve @entity1 were randomized to treatment, 351 to @entity10127 and 361 to @entity4581 . The long-term study included 438 @entity1 , 214 receiving @entity10127 and 224 receiving @entity4581 . Clinical success rates at the 2-3 week follow-up visit were 85.4% for @entity10127 and 84.6% for @entity4581 . Bacteriologic success rates were 86.7% for @entity10127 and 73.1% for @entity4581 . Significantly more @entity1 receiving @entity10127 than @entity4581 remained free of @entity3311 recurrences (71.0% vs 58.5%, respectively; P = 0.016). Both treatments were well tolerated. CONCLUSIONS: In the acute treatment of Anthonisen type 1 @entity3311 , a 5-day course of @entity10127 was at least as effective as a 7-day regimen of @entity4581 . In this population, significantly more @entity1 receiving @entity10127 remained free of @entity3311 recurrence after 26 weeks compared with those receiving @entity4581 .

A comparison of @entity10127 and XXXX in acute exacerbations of chronic @entity3617 and long-term clinical outcomes.

@entity1 :: ('9606', 'Species') :: ['participants', 'Patients', 'patients'] @entity3617 :: ('MESH:D001991', 'Disease') :: ['bronchitis'] @entity3311 :: ('MESH:D029481', 'Disease') :: ['AECB', 'acute exacerbation of chronic bronchitis'] @entity10127 :: ('MESH:C103274', 'Chemical') :: ['Gemifloxacin', 'gemifloxacin'] @entity1353 :: ('MESH:D004417', 'Disease') :: ['dyspnea'] @entity229 :: ('MESH:D011241', 'Chemical') :: ['prednisone'] @entity4581 :: ('MESH:D017291', 'Chemical') :: ['clarithromycin'] @entity230 :: ('MESH:D013256', 'Chemical') :: ['steroids'] @entity1536 :: ('CHEBI:23765', 'Chemical') :: ['quinolone']
@entity4581 :: (MESH:D017291,Chemical) :: ['clarithromycin']
